Clinical Trials Sponsored by Janssen Pharmaceutica N.V., Belgium

Total 90 results

Janssen Pharmaceutica N.V., Belgium

Recruiting

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma (MoMMent)

Relapsed/Refractory Multiple Myeloma

Germany, United Kingdom, Italy, Belgium, Spain, Netherlands, France
Janssen Pharmaceutica N.V., Belgium

Recruiting

A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice (PsABIOnd)

Arthritis, Psoriatic

Belgium, Korea, Republic of, Austria, Germany, Japan, Mexico, Greece, United Kingdom, Italy, Sweden, Spain, France, Taiwan, Netherlands, Canada, Argentina, Australia, Colombia, Russian Federation, Switzerland
Janssen Pharmaceutica N.V., Belgium

Completed

A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19

Critical Confirmed Coronavirus Disease (COVID)-19

United States
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy (COSMOS)

Arthritis, Psoriatic

Belgium, France, Israel, Italy, Germany, Bulgaria, Spain, Poland, Russian Federation, United Kingdom, Ukraine, Hungary, Portugal, Greece
Janssen Pharmaceutica N.V., Belgium

Completed

A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants

Healthy

Belgium
Janssen Pharmaceutica N.V., Belgium

Terminated

A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate Agents

Healthy

Netherlands
Janssen Pharmaceutica N.V., Belgium

Completed

A Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Participant-Reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Participants (AQUARiUS)

Prostatic Neoplasms

France, United Kingdom, Denmark
Janssen Pharmaceutica N.V., Belgium

Completed

Tracking Biologics Along the Silk Road (HARIR)

Arthritis, Rheumatoid; Spondylitis, Ankylosing; Arthritis, Psoriatic; Colitis, Ulcerative

Saudi Arabia, Egypt, Qatar, Algeria, Kuwait
Janssen Pharmaceutica N.V., Belgium

Completed

Clinical Assessment and Psychosocial Impact of Psoriasis (EPIDEPSO)

Psoriasis

France, United Kingdom, Spain, Belgium, Israel, Netherlands, Greece, South Africa, Russian Federation, Ireland, Austria, Norway
Janssen Pharmaceutica N.V., Belgium

Completed

The Prolonged Use of Topiramate for Preventing Migraine Headaches (PROMPT)

Migraine

France, Poland, United Kingdom, Belgium, Germany, Spain, Portugal, Slovenia, Bulgaria, Saudi Arabia, Switzerland, Denmark, Greece, Russian Federation, Turkey, Hungary, Austria, Ireland, Norway, Czech Republic
Janssen Pharmaceutica N.V., Belgium

Terminated

The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients

Schizophrenia | Cognition Disorders | Alzheimer's Disease

Germany
Janssen Pharmaceutica N.V., Belgium

Completed

The Effectiveness and Safety of Topiramate on Prevention of Chronic Migraine

Migraine
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation

Conduct Disorder | Oppositional Defiant Disorder | Disruptive Behavior Disorder
Janssen Pharmaceutica N.V., Belgium

Completed

A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic Schizophrenia

Psychotic Disorders | Schizophrenia
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of the Effect on Pain Control of Treatment With Fentanyl, Administered Through the Skin, in Patients With Rheumatoid Arthritis or Osteoarthritis

Arthritis | Osteoarthritis | Rheumatoid Arthritis
Janssen Pharmaceutica N.V., Belgium

Completed

Evaluation of Women's Experience With EVRA (Norelgestromin + Ethinyl Estradiol) Transdermal Contraceptive Patch Compared With Previous Methods of Contraception.

Female Contraception | Contraception
Janssen Pharmaceutica N.V., Belgium

Withdrawn

A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment (SALMONS)

Hepatitis B, Chronic

Germany, France, Italy, Spain, Denmark, Portugal, Greece
Janssen Pharmaceutica N.V., Belgium

Completed

Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets

HIV-1

United States, Spain
Janssen Pharmaceutica N.V., Belgium

Completed

A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis (PsaBio)

Psoriatic Arthritis

France, United Kingdom, Belgium, Spain, Netherlands, Greece, Russian Federation
Janssen Pharmaceutica N.V., Belgium

Terminated

A Study to Evaluate the Effect of Renal Impairment on JNJ-64417184 and Its Two Minor Metabolites JNJ-68294291 and JNJ-65201526 in Adult Participants

Renal Impairment

Germany
Janssen Pharmaceutica N.V., Belgium

Completed

A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-64041575 in Adult Participants With Various Degrees of Renal Function

Renal Insufficiency

Germany
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain.

Pain

France, Poland, Germany, Slovenia, Sweden, Czech Republic, Norway, Slovakia, Switzerland, Denmark
Janssen Pharmaceutica N.V., Belgium

Completed

A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder

Bipolar Disorder

China, Taiwan, Colombia, India, Malaysia, Russian Federation, South Africa, Greece, Peru, Germany, Mexico, Lebanon, Indonesia, Philippines, Jordan
Janssen Pharmaceutica N.V., Belgium

Completed

Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode

Schizophrenia

United Kingdom, Slovenia, Denmark, Finland, France, Greece, Israel, Norway, Sweden, Switzerland
Janssen Pharmaceutica N.V., Belgium

Completed

Interaction Between Etravirine or Darunavir/Ritonavir and Artemether / Lumefantrine (DDI Coartem)

HIV
Janssen Pharmaceutica N.V., Belgium

Completed

A Survey Study of the Treatment and Outcome Management in Patients Diagnosed With Alzheimer's Disease

Mental Disorders | Brain Diseases | Nervous System Diseases | Dementia | Alzheimer Disease
Janssen Pharmaceutica N.V., Belgium

Completed

A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset Psychosis

Schizophrenia
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)

Psychotic Disorders | Schizophrenia
Janssen Pharmaceutica N.V., Belgium

Completed

Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study

Dementia | Alzheimer Disease
Janssen Pharmaceutica N.V., Belgium

Completed

A 15-day Study to Assess the Safety and Clinical Utility of Duragesic (Fentanyl Transdermal Patch) in the Treatment of Children With Continuous Pain Requiring Narcotic Pain Relief Therapy

Chronic Pain
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of the Effectiveness and Safety of Prolonged-release Methylphenidate Hydrochloride in Adult Patients With Attention Deficit/Hyperactivity Disorder.

Attention Deficit Disorder With Hyperactivity
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of the Effect on Pain Control of Treatment With Fentanyl, Administered Through the Skin, Compared With Placebo in Patients With Osteoarthritis

Arthritis | Osteoarthritis
Janssen Pharmaceutica N.V., Belgium

Completed

EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure

Chronic Renal Failure
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia

Dementia | Alzheimer Disease | Dementia, Vascular
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of the Effectiveness and Safety of Risperidone Versus Placebo as add-on Therapy to Mood Stabilizers, in the Treatment of Manic Episodes Associated With Bipolar Disorder.

Bipolar Disorder | Manic Disorder
Janssen Pharmaceutica N.V., Belgium

Completed

RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain Information on the Safety and Efficacy of Risperidone When Used in Routine Clinical Practice

Psychotic Disorders | Schizophrenia | Schizoaffective Disorder
Janssen Pharmaceutica N.V., Belgium

Recruiting

A Study of JNJ-55308942 in the Treatment of Bipolar Depression

Bipolar Disorder

United States, Spain, Poland, Canada
Janssen Pharmaceutica N.V., Belgium

Recruiting

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (PRIMORDIUM)

Prostatic Neoplasms

Belgium, United States, Italy, Poland, Brazil, Denmark, Germany, Hungary, Mexico, Portugal, Russian Federation, Spain, Sweden, Turkey, Czechia, Finland, Austria, Australia, Lebanon, Slovakia, Jordan
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of Ponesimod in Healthy Adult Participants

Healthy

Belgium
Janssen Pharmaceutica N.V., Belgium

Terminated

A Study of JNJ-64140284 in Healthy Male Participants (AMPAR)

Healthy

Belgium
Janssen Pharmaceutica N.V., Belgium

Completed

A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical Care

Prostate Cancer

France, Poland, United Kingdom, Belgium, Germany, Spain, Israel, Portugal, Slovenia, Turkey, Sweden, Austria, Russian Federation, Luxembourg, Switzerland
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of Ponesimod in Healthy Adult Participants Receiving Propranolol at Steady State

Healthy

Belgium
Janssen Pharmaceutica N.V., Belgium

Completed

Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy

Prostate Cancer

United Kingdom, Belgium, Hungary, Germany
Janssen Pharmaceutica N.V., Belgium

Completed

Telaprevir With Peginterferon Alfa & Ribavirin in Ex-People Who INject Drugs Infected by Genotype 1 Chronic Hepatitis C (INTEGRATE)

Hepatitis, Chronic

France, United Kingdom, Belgium, Germany, Netherlands, Switzerland
Janssen Pharmaceutica N.V., Belgium

Completed

Idylla IFV-RSV Panel Clinical Testing (RP1)

Respiratory Tract Infections | Influenza, Human | Respiratory Syncytial Virus Infections

United States
Janssen Pharmaceutica N.V., Belgium

Completed

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Multiple Myeloma

France, Poland, Ukraine, Germany, Spain, Israel, Portugal, Slovenia, South Africa, Turkey, Greece, Estonia, Russian Federation, Hungary, Austria, Lithuania, Macedonia, The Former Yugoslav Republic of, Latvia, Croatia, Denmark, A...
Janssen Pharmaceutica N.V., Belgium

Completed

Non-Interventional Study of Participants With Newly Diagnosed Schizophrenia Treated With Paliperidone Palmitate

Schizophrenia

Turkey, Russian Federation, Croatia
Janssen Pharmaceutica N.V., Belgium

Completed

A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of JNJ-42165279 in Healthy Male Participants

Healthy

Belgium
Janssen Pharmaceutica N.V., Belgium

Completed

Exploratory Study on the Mood and Cytokine Levels in Female Healthy Participants and Major Depressive Disorder Patients

Major Depressive Disorder

Belgium
Janssen Pharmaceutica N.V., Belgium

Completed

Retrospective Survey of Re-treatment With Bortezomib

Multiple Myeloma | Hematological Cancer

Greece

3

Subscribe